Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors
Kenvue shares rose 22% in their trading debut in May 2023. But the honeymoon was short-lived. Barely 15 months after the spinoff, activist investors tired of anemic growth, started to demand change. Since last autumn, Starboard, Third Point Capital and Toms Capital Investment Management have all pressured the company to find ways to accelerate growth and increase profit margins.
All that culminated on Monday with the abrupt resignation of Kenvue CEO Thibaut Mongon, his replacement by board director Kirk Perry on an interim basis, and the confirmation that Kenvue is undertaking a strategic review in the hopes of 'optimizing' a sprawling portfolio and boosting profitability.
'Kenvue has world-class brands in attractive categories and a strong global platform. The actions announced today are to ensure we have the right talent, brand portfolio and operational foundation to fully capitalize on those strengths, accelerate profitable growth and best position the Company for future success,' said Larry Merlo, Kenvue's chair and the former CEO of CVS Health.
The leadership shakeup comes on the heels of a rough earnings call. Kenvue announced on Monday that in its most recent quarter, it expects net sales to fall 4%, continuing a downward trend. As a result of that weak performance, shares fell from their all time high of about $27 in 2023 to around $21.25 today. In contrast, the S&P 500 has risen more than 40% in the last two years.
Kenvue's challenges stem from the same factors that created so much optimism at its debut. J&J spun off its consumer business to focus on its highly profitable pharmaceutical businesses, much as Merck, Sanofi, Pfizer and GSK had in previous years. The goal was to streamline J&J, not make Kenvue's portfolio composition ideal from the start.
The practice is not unusual in corporate America; spinoffs are often repositories for brands the parent company did not want. But Kenvue struggled to balance and diversify its own brand portfolio, and figure out a formula that would work outside of the J&J umbrella. In retrospect, a boosterish comment from Mongon on the day of the spinoff, who had been leading J&J's consumer business since 2019, seems like a warning sign. 'We are the only company of our size covering all of consumer health,' Mongon said in 2023.
Fortune was unable to reach Mongon for comment.
Ultimately, the activists pressuring Kenvue to sell off some brands, or even consider selling itself entirely (its market capitalization is $40 billion) have prevailed. Last month, Reuters reported that Kenvue was focusing on its marquee brands like Neutrogena, and considering selling many others including Clean & Clear, Maui Moisture, Neostrata, its German baby care brand Bebe, and Japanese brand Dr.Ci:Labo.
With Perry at the helm now, Kenvue has a leader who is a veteran of Procter & Gamble, and intimately familiar with periodic portfolio resets that activists have clamored for.
But Kenvue's shares barely budged after the CEO and strategic overview news. That suggests investors are not expecting Perry—or whoever becomes permanent CEO—to turn things around quickly.
This story was originally featured on Fortune.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Here is Why ProPetro Holding (PUMP) Plunged This Week
The share price of ProPetro Holding Corp. (NYSE:PUMP) fell by 13.3% between July 11 and July 18, 2025, putting it among the Energy Stocks that Lost the Most This Week. An oil derrick silhouetted against a rising sun with a blue sky in the background. ProPetro Holding Corp. (NYSE:PUMP) is an oilfield services company that engages in the provision of hydraulic fracturing and other complementary services. ProPetro Holding Corp. (NYSE:PUMP) plunged this week following a downturn witnessed in the overall oilfield services sector, amid reports of a slowdown in drilling activity and a broader pullback in exploration and production spending. Analysts expect the sector to post a decline in earnings in the Q2 earnings season, as well as a drop in guidance for the second half of the year. Moreover, investors may also have reacted to ProPetro Holding Corp. (NYSE:PUMP) recently announcing a change in leadership, with Mr. Caleb Weatherl appointed as the company's new CFO on July 14, 2025. Following the recent decline, the share price of ProPetro Holding Corp. (NYSE:PUMP) has plunged by over 42% since the beginning of 2025. While we acknowledge the potential of PUMP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Oil and Gas Dividend Stocks to Buy Now and The 5 Energy Stocks Billionaires are Quietly Piling Into. Disclosure: None. Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Target downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The 5 Upgrades: Barclays upgraded Dollar Tree (DLTR) to Overweight from Equal Weight with a price target of $120, up from $95. The company is positioned to benefit from a trade down by consumes, which will accelerates in the second half of 2025, the firm tells investors in a research note. Morgan Stanley upgraded Pinterest (PINS) to Overweight from Equal Weight with a price target of $45, up from $37. The firm's advertising checks are constructive on Pinterest's improving ad efficiency and performance-driven growth. Morgan Stanley upgraded Etsy (ETSY) to Equal Weight from Underweight with a price target of $50, up from $38. The firm sees a more balanced catalyst path for the shares after they underperformed the S&P 500 Index by 20% over the past year. Seaport Research upgraded both Analog Devices (ADI) and Texas Instruments (TXN) to Neutral from Sell with no price target. While the firm sees "no strong catalysts," it acknowledges that it was "wrong" in its prior thought that the analog inventory cycle was not going to improve and the macro economy was slowing. Monness Crespi upgraded Fiserv (FI) to Neutral from Sell with no price target, telling investors that the firm sees fair value at about $155 per share. The firm's sense is that the market has been looking to revalue the stock as long as the Clover volume trajectory remains above double digits over the medium term and it recommends investors to "be ready" for the next opportunity. Top 5 Downgrades: Barclays downgraded Target (TGT) to Underweight from Equal Weight with an unchanged price target of $91. The firm says that absent a bigger strategic shift, the company's sales will continue to underperform. Needham downgraded Sarepta (SRPT) to Underperform from Hold without a price target. The company late Friday reported receiving an informal request from the FDA to voluntarily halt shipments of Elevidys and that it denied this request, the firm tells investors in a research note. Mizuho, Leerink, and Baird also downgraded Sarepta to Neutral-equivalent ratings, while Deutsche Bank cut its rating on the name to Sell. Truist downgraded Biogen (BIIB) to Hold from Buy with a price target of $142, down from $199, after a transfer in coverage. The stock's discounted multiple versus pees is warranted given the "suboptimal" growth outlook for Biogen's commercial franchise, the firm tells investors in a research note. Argus downgraded Elevance Health (ELV) to Hold from Buy, citing the ongoing pressures on the company's profit margins from medical cost trends in its Medicaid and ACA marketplace businesses. Truist downgraded Royal Caribbean (RCL) to Hold from Buy with a price target of $337, up from $275. Truist has observed a bounce-back in bookings since April's pullback, but when averaging March-early July's year over year bookings, demand pace is only up low-to-mid-single digits, well off the high-teens monthly pace that 2024 averaged, the firm tells investors in a research note. Top 5 Initiations: Loop Capital initiated coverage of Autodesk (ADSK) with a Hold rating and $320 price target. Loop is constructive on Autodesk's long-term prospects but believes the stock's current valuation reflects much of its expected growth and execution improvements. Benchmark initiated coverage of General Motors (GM) with a Buy rating and $65 price target, calling the stock "a compelling opportunity for investors seeking exposure to a durable, cash-generative U.S. industrial franchise with underappreciated upside potential." Oppenheimer initiated coverage of Affirm (AFRM) with an Outperform rating and $80 price target, offering 15% upside potential. The firm argues that Affirm stands out as a leader in the Buy Now, Pay Later space with its advanced underwriting, robust funding strategy, strong merchant relationships, and transparent pricing model. Stephens initiated coverage of Paylocity (PCTY) with an Equal Weight rating and $200 price target. The firm believes the company is well positioned to gain share "while navigating sub-optimal labor market conditions," but believes the valuation reflects expectations of a conservative guide with modest outperformance. Barclays initiated coverage of Kroger (KR) with an Equal Weight rating and $75 price target. The firm is positive on Kroger's post-deal refocus. Barclays also started Sprouts Farmers (SFM) with an Equal Weight and Albertsons (ACI) with an Underweight. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Core Laboratories (CLB) Falls Amid a Difficult Time for the Oilfield Services Sector
The share price of Core Laboratories Inc. (NYSE:CLB) fell by 11.35% between July 11 and July 18, 2025, putting it among the Energy Stocks that Lost the Most This Week. A drilling rig manned by engineers and oil field workers preparing to explore a new petroleum reservoir. Core Laboratories Inc. (NYSE:CLB) is a leading global provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry. Core Laboratories Inc. (NYSE:CLB) slumped this week after Stifel lowered the firm's price target from $13 to $12, while maintaining a 'Hold' rating on its shares. The move reflects the analyst's overall bearish outlook for the overall oilfield services sector, which has significantly underperformed the broader market since the beginning of 2025. The oil and gas services industry is expected to post a decline in profits this earnings season due to an overall slowdown in drilling activity, caused by falling crude oil prices and global economic uncertainty due to President Trump's tariff war. It is also expected that the guidance for the second half of this year will probably be lowered among oilfield contractors, further weighing down their stocks. While we acknowledge the potential of CLB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Oil and Gas Dividend Stocks to Buy Now and The 5 Energy Stocks Billionaires are Quietly Piling Into. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
